<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03511391</url>
  </required_header>
  <id_info>
    <org_study_id>EC2017/1678</org_study_id>
    <nct_id>NCT03511391</nct_id>
  </id_info>
  <brief_title>CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors</brief_title>
  <acronym>CHEERS</acronym>
  <official_title>CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors: CHEERS-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GZA Ziekenhuizen Campus Sint-Augustinus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Sint-Lucas Brugge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Sint-Lucas Gent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled phase II trial will investigate whether the addition of&#xD;
      stereotactic body radiotherapy to checkpoint inhibitor treatment in patients with&#xD;
      non-small-cell lung carcinoma, urothelial carcinoma, renal cell carcinoma, melanoma or&#xD;
      head-and-neck carcinoma can improve progression-free survival as compared to checkpoint&#xD;
      inhibitor monotherapy. The primary outcome is progression-free survival; secondary outcomes&#xD;
      include overall survival, response according to iRecist and Recist v1.1 and toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 9, 2018</start_date>
  <completion_date type="Anticipated">August 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 14, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>15 months</time_frame>
    <description>Progression-free survival will be defined as the time from randomization to disease progression (as per iRECIST) or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years after start trial treatment</time_frame>
    <description>Overall survival will be defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response as per RECIST</measure>
    <time_frame>12 weeks</time_frame>
    <description>Response of non-irradiated lesions will be evaluated as per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response as per iRECIST</measure>
    <time_frame>12 weeks</time_frame>
    <description>Response of non-irradiated lesions will be evaluated as per iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Related Adverse Events [safety and tolerability]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse events will be monitored as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quality of life will be assessed as per EORTC-QLQ C30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic immune response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Exploratory translational analyses will be performed using blood and fecal samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <condition>Melanoma</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic body radiotherapy concurrent with checkpoint inhibitor treatment:&#xD;
Nivolumab or Pembrolizumab or Atezolizumab + SBRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Checkpoint inhibitor treatment only:&#xD;
Nivolumab or Pembrolizumab or Atezolizumab monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab or Pembrolizumab or Atezolizumab</intervention_name>
    <description>per national standard of care</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>Immune checkpoint inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Stereotactic body radiotherapy is administered to maximally 3 lesions in 3 fractions of 8Gy prior to the second/third cycle of checkpoint inhibitors.</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>Stereotactic body radiotherapy, SABR, Stereotactic ablative radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Before patient registration, written informed consent must be given according to&#xD;
             ICH/GCP and national/local regulations.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of a solid tumour.&#xD;
&#xD;
          -  At least one extracranial tumour lesion available for radiotherapy administration.&#xD;
&#xD;
          -  Patient will receive a checkpoint inhibitor per standard of care in one of the&#xD;
             following settings (locally advanced or metastatic): melanoma (1st - 3rd line&#xD;
             nivolumab or pembrolizumab); renal cell carcinoma (2nd line nivolumab); non-small cell&#xD;
             lung carcinoma (2nd or 3rd line nivolumab, pembrolizumab or atezolizumab); urothelial&#xD;
             cell carcinoma ( 1st-3rd line nivolumab, pembrolizumab or atezolizumab); head-&amp; neck&#xD;
             squamous cell carcinoma (1st-2nd line pembrolizumab, 2nd line nivolumab).&#xD;
&#xD;
          -  Karnofsky Performance status &gt; 60.&#xD;
&#xD;
          -  Age 18 years or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior radiotherapy preventing treatment with SBRT.&#xD;
&#xD;
          -  Prior treatment with an anti-PD-(L)1 antibody.&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the&#xD;
             skin that has undergone potentially curative therapy or in situ cervical cancer or&#xD;
             prostate cancer that has undergone potentially curative therapy and with normalized&#xD;
             PSA.&#xD;
&#xD;
          -  Uncontrolled central nervous system (CNS) metastases at baseline (controlled =&#xD;
             previously-treated CNS metastases (surgery Â± radiotherapy, radiosurgery, or gamma&#xD;
             knife) and who meet both of the following criteria: a) are asymptomatic and b) have no&#xD;
             requirement for steroids or enzyme-inducing anticonvulsants), and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
          -  Any condition requiring systemic treatment with corticosteroids (&gt; 10 mg daily&#xD;
             prednisone equivalent) or other immunosuppressive medication within 14 days prior to&#xD;
             the first dose of study drug. Inhaled steroids and adrenal replacement steroid doses &gt;&#xD;
             10 mg daily prednisone equivalent are permitted in the absence of active autoimmune&#xD;
             disease.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or history of human immunodeficiency virus (HIV),&#xD;
             Hepatitis B or Hepatitis C infection.&#xD;
&#xD;
          -  Mental condition rendering the patient unable to understand the nature, scope and&#xD;
             possible consequences of the study.&#xD;
&#xD;
          -  Patient not likely to comply with the protocol; I.e. uncooperative attitude, inability&#xD;
             to return for follow-up visits and unlikely to complete the study.&#xD;
&#xD;
          -  Contraindication for radiotherapy.&#xD;
&#xD;
          -  Female subjects of childbearing potential must be willing to use an adequate method of&#xD;
             contraception for the course of the study through 120 days after the last dose of&#xD;
             study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piet Ost, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Sint-Lucas</name>
      <address>
        <city>Ghent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Lucas</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GasthuisZusters Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jules Bordet Institute</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiotherapy</keyword>
  <keyword>checkpoint inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

